Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Canrib (Olaparib) 150mg Tablets
Canrib (Olaparib) 150mg Tablets, manufactured by Adley Formulations, is a specialized medication indicated for the treatment of ovarian cancer, offering targeted therapy to inhibit cancer cell growth.
Uses of Canrib (Olaparib) 150mg Tablets
Canrib (Olaparib) 150mg Tablets are used for:
Treatment of advanced ovarian cancer.
Maintenance treatment for patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.
Benefits of Canrib (Olaparib) 150mg Tablets
Targets and inhibits poly ADP-ribose polymerase (PARP) enzymes, crucial for DNA repair in cancer cells.
Improves progression-free survival and overall survival rates in ovarian cancer patients.
Offers a well-tolerated oral formulation, enhancing convenience and compliance with therapy.
Mechanism of Action of Canrib (Olaparib) 150mg Tablets
Canrib (Olaparib) 150mg Tablets contain olaparib, a PARP inhibitor that selectively binds to and inhibits PARP enzymes. By blocking PARP activity, olaparib prevents DNA repair in cancer cells with deficient homologous recombination repair mechanisms, leading to genomic instability and cancer cell death.